報價延遲最少15分鐘:2026/01/10 19:05 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.75 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.36/-0.38
|
|
企業價值
499.45M
|
| 資產負債 |
|
每股賬面淨值
-0.03
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.57
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300. |
